https://scholars.lib.ntu.edu.tw/handle/123456789/461816
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | SHIH-HUNG YANG | en_US |
dc.contributor.author | JHE-CYUAN GUO | en_US |
dc.contributor.author | CHIUN HSU | en_US |
dc.contributor.author | SUNG-HSIN KUO | en_US |
dc.contributor.author | YU-WEN TIEN | en_US |
dc.contributor.author | ANN-LII CHENG | en_US |
dc.contributor.author | KUN-HUEI YEH | en_US |
dc.creator | Yang S.-H.;Guo J.-C.;Hsu C.;Kuo S.-H.;Yu-Wen Tien;Cheng A.-L.;Yeh K.-H. | - |
dc.date.accessioned | 2020-02-20T06:53:01Z | - |
dc.date.available | 2020-02-20T06:53:01Z | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 0929-6646 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85062360752&doi=10.1016%2fj.jfma.2019.01.015&partnerID=40&md5=1c5abdad45b0b6039e97da9a72107225 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/461816 | - |
dc.description.abstract | Background: Heavily pretreated pancreatic cancer patients have a grave prognosis. In this case series study, we evaluated the safety and efficacy of nab-paclitaxel-based chemotherapy for such patients. Methods: The data of pancreatic adenocarcinoma patients (n = 40) treated with nab-paclitaxel after the failure of gemcitabine or fluoropyrimidines at our institution in 2013–2015 were reviewed. Results: The median number of prior chemotherapy regimens was two (range, 1–6). Eighteen patients had an Eastern Cooperative Oncology Group performance status of ?2. The regimens comprised nab-paclitaxel combined with the following drugs: gemcitabine (n = 28), gemcitabine and fluoropyrimidine (n = 3), platinum and fluoropyrimidine (n = 4), fluoropyrimidine (n = 4), and irinotecan and fluoropyrimidine (n = 1). The median dose of nab-paclitaxel was 63 (range, 51–72) mg/m2/dose, with the schedule of D1/15, D1/8, and D1/8/15 followed in 23, 14, and 3 patients, respectively. The median overall survival was 5.1 (95% CI, 4.6–5.7) months. Among 32 evaluable patients, two partial responses and six stable diseases were observed. The median progression-free survival was 2.6 (95% CI, 1.9–3.2) months. Grade 3/4 leucopenia or neutropenia was observed in three and two patients, respectively. Grade 3/4 anemia was observed in four patients. Other significant (grade 3 or more) nonhematological toxicities were not frequent, except for sepsis/infection (n = 7). However, more severe anemia or sepsis/infection was significantly associated with disease control. Conclusion: In heavily pretreated pancreatic adenocarcinoma patients, low-dose nab-paclitaxel-based chemotherapy was fairly tolerable with modest efficacy. ? 2019 | - |
dc.publisher | Elsevier B.V. | - |
dc.relation.ispartof | Journal of the Formosan Medical Association | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | antineoplastic metal complex; CA 19-9 antigen; carcinoembryonic antigen; fluoropyrimidine; gemcitabine; granulocyte colony stimulating factor; irinotecan; paclitaxel; 130-nm albumin-bound paclitaxel; albuminoid; antineoplastic agent; paclitaxel; adjuvant chemotherapy; adult; aged; anemia; Article; cancer combination chemotherapy; cancer survival; clinical article; disease exacerbation; drug efficacy; drug safety; female; human; infection; leukopenia; low drug dose; lymph node metastasis; male; neutropenia; overall survival; pancreas adenocarcinoma; patient history of chemotherapy; peritoneum metastasis; progression free survival; recurrence free survival; sepsis; adenocarcinoma; cancer staging; maximum tolerated dose; middle aged; pancreas tumor; pathology; prognosis; survival analysis; Taiwan; very elderly; young adult; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Prognosis; Survival Analysis; Taiwan; Young Adult | - |
dc.title | Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1016/j.jfma.2019.01.015 | - |
dc.identifier.pmid | 30852003 | - |
dc.identifier.scopus | 2-s2.0-85062360752 | - |
dc.relation.pages | 97-105 | - |
dc.relation.journalvolume | 119 | - |
dc.relation.journalissue | 1P1 | - |
item.fulltext | no fulltext | - |
item.openairetype | journal article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Radiation Oncology-NTUCC | - |
crisitem.author.dept | Division of Radiation Oncology | - |
crisitem.author.dept | Surgery | - |
crisitem.author.dept | Surgery-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Cancer Administration and Coordination Center | - |
crisitem.author.orcid | 0000-0002-6689-9640 | - |
crisitem.author.orcid | 0000-0002-1122-0055 | - |
crisitem.author.orcid | 0000-0003-0054-887X | - |
crisitem.author.orcid | 0000-0002-9126-2705 | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.orcid | 0000-0002-7306-174X | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | Oncology-NTUH | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。